[{"orgOrder":0,"company":"Remington Pharmaceuticals","sponsor":"TB Alliance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"PAKISTAN","productType":"Antibiotic","year":"2023","type":"Partnership","leadProduct":"Pretomanid","moa":"Mycolic acid biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Remington Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Remington Pharmaceuticals \/ TB Alliance","highestDevelopmentStatusID":"15","companyTruncated":"Remington Pharmaceuticals \/ TB Alliance"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"TB Alliance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Licensing Agreement","leadProduct":"Pretomanid","moa":"Mycolic acid biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fosun Pharmaceutical \/ TB Alliance","highestDevelopmentStatusID":"15","companyTruncated":"Fosun Pharmaceutical \/ TB Alliance"},{"orgOrder":0,"company":"TB Alliance","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Partnership","leadProduct":"Pretomanid","moa":"||Mycolic acid biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TB Alliance","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TB Alliance \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"TB Alliance \/ Lupin Ltd"},{"orgOrder":0,"company":"TB Alliance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Linezolid","moa":"||Adenosine triphosphatase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TB Alliance","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TB Alliance \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TB Alliance \/ Inapplicable"},{"orgOrder":0,"company":"TB Alliance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Pretomanid","moa":"||Mycolic acid biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TB Alliance","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TB Alliance \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TB Alliance \/ Inapplicable"},{"orgOrder":0,"company":"TB Alliance","sponsor":"Australian Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Linezolid","moa":"||Adenosine triphosphatase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TB Alliance","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TB Alliance \/ Australian Government","highestDevelopmentStatusID":"8","companyTruncated":"TB Alliance \/ Australian Government"}]

Find Clinical Drug Pipeline Developments & Deals for Pretomanid

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : Funding supports the NC-009 Pan-Phase 2 trial of TBAJ-876 combined with pretomanid and linezolid for treating drug-sensitive and resistant tuberculosis.

                          Product Name : TBAJ-876

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 24, 2024

                          Lead Product(s) : TBAJ-876,Linezolid,Pretomanid

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Australian Government

                          Deal Size : $11.0 million

                          Deal Type : Funding

                          blank

                          02

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : TBAJ-876 is a diarylquinoline antibiotic that targets a key enzyme of TB bacteria involved in energy production, it is being evaluated in combination with pretomanid and linezolid, for the treatment for both drug-sensitive and drug-resistant TB.

                          Product Name : TBAJ-876

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 16, 2023

                          Lead Product(s) : TBAJ-876,Linezolid,Pretomanid

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : Under the partnership, Remington will commercialize the anti-tuberculosis medicine, pretomanid as part of the all-oral, six-month BPaL and BPaLM regimens for treatment of drug-resistant TB (comprised of bedaquiline, pretomanid, and linezolid) in Pakistan...

                          Product Name : Pretomanid-Generic

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          August 14, 2023

                          Lead Product(s) : Pretomanid

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : TB Alliance

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          04

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : Lupin intends to commercialize the anti-tuberculosis (TB) medicine, Pretomanid, in approximately 140 countries and territories, including many of the highest TB burden countries around the world.

                          Product Name : PA-824

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          June 09, 2021

                          Lead Product(s) : Pretomanid,Bedaquiline,Linezolid

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Lupin Ltd

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          05

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : The new drug was authorised as part of a three-drug, six month, all-oral regimen for the treatment of adults with extensively drug-resistant TB (XDR-TB) or multidrug-resistant TB (MDR-TB) who are treatment-intolerant or non-responsive.

                          Product Name : PA-824

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          March 08, 2020

                          Lead Product(s) : Pretomanid,Bedaquiline,Linezolid

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : The partnership with Hongqi is part of TB Alliance’s global commercialization strategy for pretomanid as part of the BPaL regimen.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          January 16, 2020

                          Lead Product(s) : Pretomanid

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : TB Alliance

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank